Chiasma Investors

32 investors on Angel Roster list Chiasma in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Series B and the largest groups are based in the United States, the United Kingdom and Canada.

Investors are matched on the company name in their portfolio, so companies that share the name Chiasma can appear together.

Investors listed
32
With verified email
53%
Most common stage
Series B
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 32 Chiasma investors

The most complete profiles first. Showing 32 of 32.

  • Jonathan LeffVerified

    Venture Capital, Investor · United States

    SeedSeries BHealth CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 66 more

    Verified email available

  • Ken HaasVerified

    Venture Capital, Advisor, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Sarah BhagatVerified

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Verified email available

  • andrew sinclairVerified

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Alan ColowickVerified

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Verified email available

  • Brian GoodmanVerified

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Christopher McClearyVerified

    Venture Capital, Private Equity Firm, Finance Operator · United States

    AdvertisingHealth CareTelecommunicationsData Science

    Portfolio: LifeHarbor, Bidtellect - Native Intelligence, Union Spring Pharmaceuticals, Sedona Systems and 45 more

    Verified email available

  • Jack WyantVerified

    Venture Capital, Private Equity Firm, Finance Operator · United States

    AdvertisingHealth CareTelecommunicationsData Science

    Portfolio: LifeHarbor, Bidtellect - Native Intelligence, Union Spring Pharmaceuticals, Sedona Systems and 45 more

    Verified email available

  • Jason PittsVerified

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Verified email available

  • Luke EvninVerified

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Mark WrightVerified

    Venture Capital, Private Equity Firm, Finance Operator · United States

    AdvertisingHealth CareTelecommunicationsData Science

    Portfolio: LifeHarbor, Bidtellect - Native Intelligence, Union Spring Pharmaceuticals, Sedona Systems and 45 more

    Verified email available

  • Mike PowellVerified

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Verified email available

  • Shelley ChuVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Shinichiro FuseVerified

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Tim HainesVerified

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Todd FoleyVerified

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Bali Muralidhar

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more

    Contact details available

  • Brian Gallagher, Jr.

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more

    Contact details available

  • Ed Hurwitz

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, Protego Biopharma, InformedDNA, Mitobridge and 60 more

    Contact details available

  • Kurt von Emster

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareWomen FoundedInvestment ManagementLife Science

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Maha Katabi, PhD, CFA

    Hedge Fund, Venture Capital, Investor · Canada

    SeedHealth CareGeneticsWomen FoundedInvestment Management

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 64 more

    Contact details available

  • Perry Nisen

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Contact details available

  • Stephen Curtis

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Vin Miles

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Alfred Yue

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Contact details available

  • Christiana Bardon M.D.

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsInvestment ManagementLife Science

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Hooman Shahlavi

    Hedge Fund, Venture Capital · United States

    Health CareGeneticsWomen FoundedInvestment Management

    Portfolio: ENYO Pharma, Y-mAbs Therapeutics, NuCana, Histogenics and 63 more

    Contact details available

  • John Heard

    Venture Capital, Private Equity Firm · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Leigh Zawel

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Sarah Shackelton

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Vinay Bhaskar

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Bard GeesamanVerified

    Venture Capital

    Portfolio: Chiasma

    Verified email available

Frequently asked questions

How many Chiasma investors are on Angel Roster?

Angel Roster lists 32 Chiasma investors. 17 of them (53%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (32), Private Equity Firms (16) and Investment Partner Investors (3). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do Chiasma investors invest in?

Among those that list a stage, the most common are Series B (7) and Seed (6).

Where are Chiasma investors based?

Most are based in the United States (25), the United Kingdom (5) and Canada (1).

Which companies have Chiasma investors backed?

The most-backed portfolio companies among them are Proteon Therapeutics (19), Valeritas (19), Tizona Therapeutics (19), Vera Therapeutics (19) and Atsena Therapeutics (19).

How do I contact Chiasma investors?

Create a free Angel Roster account to search and filter all 32, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.